Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has increased by 0.81 compared to its previous closing price of 45.01. However, the company has seen a -0.25% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-29 that WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
The stock has a 36-month beta value of 1.07. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DYN is 73.99M, and at present, short sellers hold a 9.97% of that float. On August 29, 2024, the average trading volume of DYN was 1.05M shares.
DYN’s Market Performance
The stock of Dyne Therapeutics Inc (DYN) has seen a -0.25% decrease in the past week, with a 5.75% rise in the past month, and a 45.44% gain in the past quarter. The volatility ratio for the week is 3.58%, and the volatility levels for the past 30 days are at 5.30% for DYN. The simple moving average for the past 20 days is 2.66% for DYN’s stock, with a 68.97% simple moving average for the past 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Chardan Capital Markets repeating the rating for DYN by listing it as a “Buy.” The predicted price for DYN in the upcoming period, according to Chardan Capital Markets is $42 based on the research report published on May 21, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see DYN reach a price target of $40. The rating they have provided for DYN stocks is “Overweight” according to the report published on April 30th, 2024.
H.C. Wainwright gave a rating of “Buy” to DYN, setting the target price at $36 in the report published on February 20th of the current year.
DYN Trading at 10.68% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.37% of loss for the given period.
Volatility was left at 5.30%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares surge +7.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.32% upper at present.
During the last 5 trading sessions, DYN fell by -0.66%, which changed the moving average for the period of 200-days by +419.43% in comparison to the 20-day moving average, which settled at $44.36. In addition, Dyne Therapeutics Inc saw 241.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Kersten Dirk, who sale 89,497 shares at the price of $45.30 back on Aug 26 ’24. After this action, Kersten Dirk now owns 630,964 shares of Dyne Therapeutics Inc, valued at $4,054,408 using the latest closing price.
Kersten Dirk, the Director of Dyne Therapeutics Inc, sale 65,403 shares at $44.28 during a trade that took place back on Aug 27 ’24, which means that Kersten Dirk is holding 565,561 shares at $2,896,045 based on the most recent closing price.
Stock Fundamentals for DYN
Current profitability levels for the company are sitting at:
- -71.56 for the present operating margin
- 0.49 for the gross margin
The net margin for Dyne Therapeutics Inc stands at -68.0. The total capital return value is set at -0.34. Equity return is now at value -52.46, with -47.82 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.52. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -160.5.
Currently, EBITDA for the company is -239.7 million with net debt to EBITDA at 2.16. When we switch over and look at the enterprise to sales, we see a ratio of 1051.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.63.
Conclusion
To sum up, Dyne Therapeutics Inc (DYN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
